Similarly, in the context of breast cancer, apatinib has been observed to downregulate the Nrf2/HO-1 signaling pathway and suppress glutathione levels; this leads to ROS generation, which facilitates ROS-dependent autophagy and apoptosis, and ultimately results in the inhibition of both the proliferation and migration of breast cancer cells 147. Here, NFE2L2 is linked to breast cancer.